# US 2003/0203918 A1 · Pharmaceutical composition comprising an anticholinergic and a heterocyclic compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0203918 A1
- Document ID: US20030203918A1
- Status: Published application
- Kind: A1
- Application number: 10/358,947
- Filed: 2003-02-05
- Published: 2003-10-30
- Earliest claimed: 2002-02-08
- Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG
- Inventors: Christopher John Montague Meade; Michel Pairet; Michael P. Pieper
- Web page: https://patentgrep.com/patent/US20030203918A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/08: Bronchodilators
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for treating an inflammatory or obstructive disease of the respiratory tract which comprises administering therapeutically effective amounts of both an anticholinergic and a compound of the formula (2) 1 as well as pharmaceutical compositions comprising an anticholinergic and a compound of the formula (2).

## Claims

### Claim 1

1) A pharmaceutical composition comprising an anticholinergic and a compound of the formula (2)
194
wherein
R1 may represent hydrogen, methyl, ethyl, n-butyl, i-butyl, phenyl, 2-ethylphenyl, 2-i-propylphenyl, benzyl, 4-pyridyl, 2-pyridyl, —CO-phenyl, CN or together with R2 may represent a butylene or pentylene bridge;
R2 may represent hydrogen, methyl, ethyl, or together with R1 may represent a butylene or pentylene bridge, or together with R13 may represent a single bond or a butylene bridge;
R3 may represent hydrogen;
R4 may represent methoxy;
R5 may represent cyclohexyl, phenyl, 3-methoxycarbonylphenyl, 4-methoxycarbonylphenyl, 3-carboxyphenyl, 4-carboxyphenyl, CN, —COOH, —COOMe, —COOEt, 3,5-dichloro-pyridin-4-yl, 4-pyridyl or 4-pyridyl-N-oxide;
A may represent oxygen or —CH2—;
B may represent oxygen or one of the groups —C(R12)(R13) or —CH(R15)—CH(R17);
D may represent a group selected from —CH2—CH2, —CH(Ph)—CH2, —CONH, —CO—CH2, —CH═CH, —C(Ph)═CH, —C(CR18)(CR19)—X, —C(R19a)═Y, —C═C or phenylene;
R12 may represent hydrogen, methyl, ethyl, i-propyl, phenyl or —CH2—CORx;
R13 may represent hydrogen or together with R2 may represent a single bond or a butylene bridge;
R15 may represent hydrogen or together with R17 may represent a single bond;
R17 may represent hydrogen or
together with R15 may represent a single bond;
R18 may represent hydrogen or methyl;
R19 may represent hydrogen, methoxy, phenyl or CN;
R19a may represent hydrogen, methyl or phenyl;
Rx may represent hydroxy, ethoxy, benzyloxy, 2-phenylethyloxy, 4-methylpiperazin-1-yl, 4-phenylpiperazin-1-yl, N-tetrahydroisoquinolinyl, —NH-phenyl, —NH-benzyl, —NH—CH2-(4-methoxyphenyl), —NH—CH2-(4-fluorophenyl), —NH—CH12-(4-chlorophenyl), —NH—CH2-(2-chlorophenyl), —NH-(3-pyridyl), —NH—CH2-(2-pyridyl), —NH—CH2-(3-pyridyl), —NH—CH2-(4-pyridyl), —NH-(3,5-dichloropyridin-4-yl) or —NH-(2-pyrimidinyl);
X may represent —CH2, —S or —NH—
Y may represent CH, CCN, CCOOEt or CHCONH,
or a pharmacologically acceptable acid addition salt thereof, and a pharmaceutically acceptable excipient.

### Claim 2 (depends on 1)

2) A pharmaceutical composition according to claim 1, wherein the anticholinergic is selected from the group consisting of the pharmacologically acceptable salts of tiotropium, oxitropium and ipratropium.

### Claim 3 (depends on 2)

3) A pharmaceutical composition according to claim 2, wherein the anticholinergic is present in the form of the chloride, bromide, iodide, methanesulphonate or paratoluenesulphonate.

### Claim 4 (depends on 1)

4) A pharmaceutical composition according to claim 1, wherein the compound of formula 2 is a compound of formula 2a,
195
wherein
R1 may represent hydrogen, n-butyl, benzyl, 4-pyridyl, 2-pyridyl, —CO-phenyl or CN;
R2 may represent hydrogen or
together with R13 may represent a single bond;
R5 may represent cyclohexyl, phenyl, 3,5-dichloro-pyridin-4-yl or 4-pyridyl;
R12 may represent hydrogen, methyl, ethyl, i-propyl, phenyl or —CH2—CORx;
R13 may represent hydrogen or
together with R2 may represent a single bond;
Rx may represent hydroxy, ethoxy, benzyloxy, 2-phenylethoxy, 4-methylpiperazin-1-yl, 4-phenylpiperazin-1-yl, N-tetrahydroisoquinolinyl, —NH-phenyl, —NH-benzyl, —NH—CH2-(4-methoxyphenyl), —NH—CH2-(4-fluorophenyl), —NH—CH2-(4-chlorophenyl), —NH—CH2-(2-chlorophenyl), —NH-(3-pyridyl), —NH—CH2-(2-pyridyl), —NH—CH2-(3-pyridyl), —NH—CH2-(4-pyridyl), —NH-(3,5-dichloropyridin-4-yl) or —NH-(2-pyrimidinyl),
or a pharmacologically acceptable acid addition salt thereof.

### Claim 5 (depends on 1)

5) A pharmaceutical composition according to claim 1, wherein the compound of formula 2 is a compound of formula 2b,
196
wherein
R1 may represent hydrogen, methyl, ethyl or 4-pyridyl, or
together with R2 may represent a butylene bridge;
R2 may represent hydrogen, methyl, ethyl, or
together with R1 may represent a butylene bridge, or
together with R13 may represent a single bond;
R5 may represent 3,5-dichloro-pyridin-4-yl or 4-pyridyl;
R12 may represent hydrogen or methyl;
R13 may represent hydrogen or
together with R2 may represent a single bond;
R18 may represent hydrogen or methyl;
R19 may represent hydrogen, methoxy, phenyl or CN;
X may represent —CH2, —S or —NH—,
or a pharmacologically acceptable acid addition salt thereof.

### Claim 6 (depends on 1)

6) A pharmaceutical composition according to claim 1, wherein the compound of formula 2 is a compound of formula 2c,
197
wherein
R1 may represent hydrogen, methyl, ethyl, phenyl, 4-pyridyl, 2-pyridyl, or
together with R2 may represent a butylene or pentylene bridge;
R2 may represent hydrogen, methyl, ethyl, or
together with R1 may represent a butylene or pentylene bridge, or
together with R13 may represent a single bond; R5 may represent 3-methoxycarbonylphenyl, 4-methoxycarbonylphenyl, 3-carboxyphenyl, 4-carboxyphenyl, CN, —COOEt, 3,5-dichloro-pyridin-4-yl or 4-pyridyl;
R12 may represent hydrogen or methyl;
R13 may represent hydrogen or
together with R2 may represent a single bond;
R19a may represent hydrogen, methyl or phenyl;
Y may represent CH, CCN, CCOOEt or CHCONH,
or a pharmacologically acceptable acid addition salt thereof.

### Claim 7 (depends on 1)

7) A pharmaceutical composition according to claim 1, wherein the compound of formula 2 is a compound of formula 2d,
198
wherein
R1 may represent hydrogen, methyl, ethyl, n-butyl, i-butyl, phenyl, 2-ethylphenyl, 2-i-propylphenyl, 4-pyridyl, 2-pyridyl, —CO-phenyl, CN, or
together with R2 may represent a butylene or pentylene bridge;
R2 may represent hydrogen, methyl, ethyl, or
together with R1 may represent a butylene or pentylene bridge, or
together with R13 may represent a single bond or a butylene bridge;
R5 may represent phenyl, 3,5-dichloro-pyridin-4-yl or 4-pyridyl;
R12 may represent hydrogen, methyl, phenyl or —CH2—CORx;
R13 may represent hydrogen or
together with R2 may represent a single bond or a butylene bridge;
Rx may represent ethoxy,
or a pharmacologically acceptable acid addition salt thereof.

### Claim 8 (depends on 1)

8) A pharmaceutical composition according to claim 1, wherein the compound of formula 2 is a compound of formula 2e,
199
wherein
R1 may represent methyl or
together with R2 may represent a butylene or pentylene bridge;
R2 may represent methyl or
together with R1 may represent a butylene or pentylene bridge;
R5 may represent 3,5-dichloro-pyridin-4-yl or 4-pyridyl;
D may represent a group selected from —CONH, —CO—CH2 or —CH═CH—;
R15 may represent hydrogen or
together with R17 may represent a single bond;
R17 may represent hydrogen or
together with R15 may represent a single bond,
or a pharmacologically acceptable acid addition salt thereof.

### Claim 9 (depends on 1)

9) A pharmaceutical composition according to claim 1, wherein the compound of formula 2 is a compound of formula 2f,
200
wherein
R5 may represent 3,5-dichloro-pyridin-4-yl or 4-pyridyl;
D may represent a group selected from —CONH, —CO—CH2 or —CH═CH—, optionally
or a pharmacologically acceptable acid addition salt thereof.

### Claim 10 (depends on 1)

10) A pharmaceutical composition according to claim 1, wherein the compound of formula 2 is a compound of formula 1g,
201
wherein
R5 may represent 3,5-dichloro-pyridin-4-yl or 4-pyridyl;
D may represent a group selected from —CH2—CH2, —CH(Ph)—CH2, —CONH, —CO—CH2, —CH═CH or —C(Ph)═CH—,
or a pharmacologically acceptable acid addition salt thereof.

### Claim 11 (depends on 1)

11) A pharmaceutical composition according to claim 1, wherein the compound of formula 2 is a compound of formula 2h,
202
wherein
W may represent a group selected from among
203
or a pharmacologically acceptable acid addition salt thereof.

### Claim 12 (depends on 1)

12) A pharmaceutical composition according to claim 1, wherein the weight ratio of the anticholinergic to the compound of the formula 2 are in the range from 1:300 to 50:1, preferably from 1:250 to 40:1.

### Claim 13

13) A method for treating an inflammatory or obstructive disease of the respiratory tract which comprises administering therapeutically effective amounts of both an anticholinergic and a compound of the formula (2)
204
R1 may represent hydrogen, methyl, ethyl, n-butyl, i-butyl, phenyl, 2-ethylphenyl, 2-i-propylphenyl, benzyl, 4-pyridyl, 2-pyridyl, —CO-phenyl, CN or
together with R2 may represent a butylene or pentylene bridge;
R2 may represent hydrogen, methyl, ethyl, or
together with R1 may represent a butylene or pentylene bridge, or
together with R13 may represent a single bond or a butylene bridge;
R3 may represent hydrogen;
R4 may represent methoxy;
R5 may represent cyclohexyl, phenyl, 3-methoxycarbonylphenyl, 4-methoxycarbonylphenyl, 3-carboxyphenyl, 4-carboxyphenyl, CN, —COOH, —COOMe, —COOEt, 3,5-dichloro-pyridin-4-yl, 4-pyridyl or 4-pyridyl-N-oxide;
A may represent oxygen or —CH2—;
B may represent oxygen or one of the groups —C(R12)(R13) or —CH(R15)—CH(R17);
D may represent a group selected from —CH2—CH2, —CH(Ph)—CH2, —CONH, —CO—CH2, —CH═CH, —C(Ph)═CH, —C(CR18)(CR19)—X, —C(R19a)═Y, —C═C or phenylene;
R12 may represent hydrogen, methyl, ethyl, i-propyl, phenyl or —CH2—CORx;
R13 may represent hydrogen or
together with R2 may represent a single bond or a butylene bridge;
R15 may represent hydrogen or
together with R17 may represent a single bond;
R17 may represent hydrogen or
together with R15 may represent a single bond;
R18 may represent hydrogen or methyl;
R19 may represent hydrogen, methoxy, phenyl or CN;
R19a may represent hydrogen, methyl or phenyl;
Rx may represent hydroxy, ethoxy, benzyloxy, 2-phenylethyloxy, 4-methylpiperazin-1-yl, 4-phenylpiperazin-1-yl, N-tetrahydroisoquinolinyl, —NH-phenyl, —NH-benzyl, —NH—CH2-(4-methoxyphenyl), —NH—CH2-(4-fluorophenyl), —NH—CH2-(4-chlorophenyl), —NH—CH2-(2-chlorophenyl), —NH-(3-pyridyl), —NH—CH2-(2-pyridyl), —NH—CH2-(3-pyridyl), —NH—CH2-(4-pyridyl), —NH-(3,5-dichloropyridin-4-yl) or —NH-(2-pyrimidinyl);
X may represent —CH2, —S or —NH—
Y may represent CH, CCN, CCOOEt or CHCONH,
or a pharmacologically acceptable acid addition salt thereof, and a pharmaceutically acceptable excipient.

### Claim 14 (depends on 13)

14) The method according to claim 13, wherein the anticholinergic is selected from the group consisting of the pharmacologically acceptable salts of tiotropium, oxitropium and ipratropium.

### Claim 15 (depends on 14)

15) The method according to claim 14, wherein the anticholinergic is present in the form of the chloride, bromide, iodide, methanesulphonate or para-toluenesulphonate.

### Claim 16 (depends on 13)

16) The method according to claim 13, wherein the compound of formula 2 is a compound of formula 2a,
205
wherein
R1 may represent hydrogen, n-butyl, benzyl, 4-pyridyl, 2-pyridyl, —CO-phenyl or CN;
R2 may represent hydrogen or
together with R13 may represent a single bond;
R5 may represent cyclohexyl, phenyl, 3,5-dichloro-pyridin-4-yl or 4-pyridyl;
R12 may represent hydrogen, methyl, ethyl, i-propyl, phenyl or —CH2—CORx;
R13 may represent hydrogen or
together with R2 may represent a single bond;
Rx may represent hydroxy, ethoxy, benzyloxy, 2-phenylethoxy, 4-methylpiperazin-1-yl, 4-phenylpiperazin-1-yl, N-tetrahydroisoquinolinyl, —NH-phenyl, —NH-benzyl, —NH—CH2-(4-methoxyphenyl), —NH—CH2-(4-fluorophenyl), —NH—CH2-(4-chlorophenyl), —NH—CH2-(2-chlorophenyl), —NH-(3-pyridyl), —NH—CH2-(2-pyridyl), —NH—CH2-(3-pyridyl), —NH—CH2-(4-pyridyl), —NH-(3,5-dichloropyridin-4-yl) or —NH-(2-pyrimidinyl),
or a pharmacologically acceptable acid addition salt thereof.

### Claim 17 (depends on 13)

17) The method according to claim 13, wherein the compound of formula 2 is a compound of formula 2b,
206
wherein
R1 may represent hydrogen, methyl, ethyl or 4-pyridyl, or
together with R2 may represent a butylene bridge;
R2 may represent hydrogen, methyl, ethyl, or
together with R1 may represent a butylene bridge, or
together with R13 may represent a single bond;
R5 may represent 3,5-dichloro-pyridin-4-yl or 4-pyridyl;
R12 may represent hydrogen or methyl;
R13 may represent hydrogen or
together with R2 may represent a single bond;
R18 may represent hydrogen or methyl;
R19 may represent hydrogen, methoxy, phenyl or CN;
X may represent —CH2, —S or —NH—,
or a pharmacologically acceptable acid addition salt thereof.

### Claim 18 (depends on 13)

18) The method according to claim 13, wherein the compound of formula 2 is a compound of formula 2c,
207
wherein
R1 may represent hydrogen, methyl, ethyl, phenyl, 4-pyridyl, 2-pyridyl, or
together with R2 may represent a butylene or pentylene bridge;
R2 may represent hydrogen, methyl, ethyl, or
together with R1 may represent a butylene or pentylene bridge, or
together with R13 may represent a single bond;
R5 may represent 3-methoxycarbonylphenyl, 4-methoxycarbonylphenyl, 3-carboxyphenyl, 4-carboxyphenyl, CN, —COOEt, 3,5-dichloro-pyridin-4-yl or 4-pyridyl;
R12 may represent hydrogen or methyl;
R13 may represent hydrogen or
together with R2 may represent a single bond;
R19a may represent hydrogen, methyl or phenyl;
Y may represent CH, CCN, CCOOEt or CHCONH,
or a pharmacologically acceptable acid addition salt thereof.

### Claim 19 (depends on 13)

19) The method according to claim 13, wherein the compound of formula 2 is a compound of formula 2d,
208
wherein
R1 may represent hydrogen, methyl, ethyl, n-butyl, i-butyl, phenyl, 2-ethylphenyl, 2-i-propylphenyl, 4-pyridyl, 2-pyridyl, —CO-phenyl, CN, or
together with R2 may represent a butylene or pentylene bridge;
R2 may represent hydrogen, methyl, ethyl, or
together with R1 may represent a butylene or pentylene bridge, or
together with R13 may represent a single bond or a butylene bridge;
R5 may represent phenyl, 3,5-dichloro-pyridin-4-yl or 4-pyridyl;
R12 may represent hydrogen, methyl, phenyl or —CH2—CORx;
R13 may represent hydrogen or
together with R2 may represent a single bond or a butylene bridge;
Rx may represent ethoxy,
or a pharmacologically acceptable acid addition salt thereof.

### Claim 20 (depends on 13)

20) The method according to claim 13, wherein the compound of formula 2 is a compound of formula 2e,
209
wherein
R1 may represent methyl or
together with R2 may represent a butylene or pentylene bridge;
R2 may represent methyl or
together with R1 may represent a butylene or pentylene bridge;
R5 may represent 3,5-dichloro-pyridin-4-yl or 4-pyridyl;
D may represent a group selected from —CONH, —CO—CH2 or —CH═CH—;
R15 may represent hydrogen or
together with R17 may represent a single bond;
R17 may represent hydrogen or
together with R15 may represent a single bond,
or a pharmacologically acceptable acid addition salt thereof.

### Claim 21 (depends on 13)

21) The method according to claim 13, wherein the compound of formula 2 is a compound of formula 2f,
210
wherein
R5 may represent 3,5-dichloro-pyridin-4-yl or 4-pyridyl;
D may represent a group selected from —CONH, —CO—CH2 or —CH═CH—, optionally
or a pharmacologically acceptable acid addition salt thereof.

### Claim 22 (depends on 13)

22) The method according to claim 13, wherein the compound of formula 2 is a compound of formula 2g,
211
wherein
R5 may represent 3,5-dichloro-pyridin-4-yl or 4-pyridyl;
D may represent a group selected from —CH2—CH2, —CH(Ph)—CH2, —CONH, —CO—CH2, —CH═CH or —C(Ph)═CH—,
or a pharmacologically acceptable acid addition salt thereof.

### Claim 23 (depends on 13)

23) The method according to claim 13, wherein the compound of formula 2 is a compound of formula 2h,
212
wherein
W may represent a group selected from among
213
or a pharmacologically acceptable acid addition salt thereof.
